Elicera Therapeutics (ELIC) Q3 2025 earnings summary

Executive summary

• Achieved operating profit of SEK 146,689 in Q3 2025, a significant improvement from SEK -2,697,267 in Q3 2024, driven by increased grant income and higher costs.

• Loss for the period narrowed to SEK -10,441,379 for Jan–Sep 2025 from SEK -13,507,085 year-over-year.

• Key clinical progress in CARMA study: 4 of 6 patients at lowest dose showed complete metabolic response, with no serious adverse events.

• ELC-100 received Orphan Drug Designation in the U.S. for pancreatic neuroendocrine tumors.

• Raised SEK 22.0 million through new share subscription and directed issue.

Financial highlights

• Q3 2025 operating profit: SEK 146,689 (Q3 2024: SEK -2,697,267); Jan–Sep 2025 operating loss: SEK -10,815,056 (Jan–Sep 2024: SEK -13,972,098).

• Earnings per share for Q3 2025: SEK +0.01 (Q3 2024: SEK -0.07); Jan–Sep 2025: SEK -0.23 (Jan–Sep 2024: SEK -0.45).

• Cash flow from operating activities for Jan–Sep 2025: SEK -11,474,233 (Jan–Sep 2024: SEK -19,231,075).

• Cash and cash equivalents at period end: SEK 34,923,463 (Sep 2024: SEK 30,631,198).

Outlook and guidance

• CARMA study continues with patient recruitment in the highest dose cohort; preliminary data from this group expected in spring 2026.

• Final reporting of ELC-100 Phase I/II study postponed to turn of 2025/2026 due to database transition.

• Ongoing efforts to secure soft funding and partnerships for preclinical programs, especially ELC-401 for glioblastoma.